Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06511895
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-15
Brief Title:
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma JACKPOT27
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Open-Label Single-Arm Study to Investigate the Safety Tolerability and Anti-tumor Activity of AZD4205 Treating Relapsed or Refractory Peripheral T Cell Lymphoma rr PTCL
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II open label multicenter study of AZD4205 administered orally in participants with rr PTCL to determine its safety tolerability PK and anti-tumor activity Eligible participants are those who had pathologically confirmed PTCL and have relapsed after or been refractoryintolerant to at least one prior systemic treatment regimen The primary objective of this study is to evaluate anti-tumor efficacy of AZD4205 at 150 mg once daily RP2D in participants with rr PTCL The safety tolerability and PK of AZD4205 in rr PTCL at RP2D will also be investigated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None